At the 44th Annual J.P. Morgan Healthcare Conference, CEO Prahlad Singh detailed Revvity’s shift from a diversified industrial portfolio to a focused health sciences leader. Over the past three years, the company divested non-core small-molecule preclinical operations and enhanced diagnostics capabilities, resulting in diagnostics now representing roughly 40% of total revenue. Singh highlighted investments in translational multi-omics and biomarker platforms, noting that these initiatives have driven a 12% compound annual growth rate in high-margin workflow services since 2022. Management reaffirmed its commitment to end-to-end solutions spanning discovery to diagnosis, citing partnerships with top biopharma firms and leading academic centers in more than 160 countries.

Revvity reported preliminary fourth-quarter revenue of approximately $772 million, up 6% year-over-year on a reported basis and 4% organically after adjusting for foreign exchange. For the full year 2025, revenue reached about $2.855 billion, reflecting 4% reported growth and 3% organic growth versus 2024. These results surpassed prior guidance, driven by accelerating demand in contract research and diagnostic services. Management now expects adjusted earnings per share for full-year 2025 to exceed the previously guided range of $4.90 to $5.00, reflecting tighter cost controls and scale benefits across its service lines.

Looking ahead, Revvity projects organic revenue growth of 5% to 7% in 2026, supported by expansion in informatics and imaging solutions and planned launches in predictive diagnostics. The company plans to reinvest roughly 8% of revenue into R&D, targeting next-generation multi-omics assays and AI-driven analytics tools. However, management cautioned that foreign exchange volatility and integration of recent acquisitions could introduce earnings variability. Key risk factors include potential delays in regulatory approvals for new platforms and fluctuations in customer capital spending patterns among pharmaceutical partners.